216 related articles for article (PubMed ID: 17681022)
1. Patterns of triptans use: a study based on the records of a community pharmaceutical department.
Pavone E; Banfi R; Vaiani M; Panconesi A
Cephalalgia; 2007 Sep; 27(9):1000-4. PubMed ID: 17681022
[TBL] [Abstract][Full Text] [Related]
2. Triptans: low utilization and high turnover in the general population.
Panconesi A; Pavone E; Franchini M; Mennuti N; Bartolozzi M; Guidi L; Banfi R
Cephalalgia; 2010 May; 30(5):576-81. PubMed ID: 19732070
[TBL] [Abstract][Full Text] [Related]
3. Triptan persistency among newly initiated users in a pharmacy claims database.
Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
[TBL] [Abstract][Full Text] [Related]
4. Intensive community pharmacy intervention had little impact on triptan consumption: a randomized controlled trial.
Søndergaard J; Foged A; Kragstrup J; Gaist D; Gram LF; Sindrup SH; Muckadell HU; Larsen BO; Herborg H; Andersen M
Scand J Prim Health Care; 2006 Mar; 24(1):16-21. PubMed ID: 16464810
[TBL] [Abstract][Full Text] [Related]
5. Patterns of specific antimigraine drug use--a study based on the records of 18 community pharmacies.
Lohman JJ; van der Kuy-de Ree MM;
Cephalalgia; 2005 Mar; 25(3):214-8. PubMed ID: 15689197
[TBL] [Abstract][Full Text] [Related]
6. Triptans in the Italian population: a drug utilization study and a literature review.
Panconesi A; Pavone E; Vacca F; Vaiani M; Banfi R
J Headache Pain; 2008 Apr; 9(2):71-6. PubMed ID: 18317865
[TBL] [Abstract][Full Text] [Related]
7. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
[TBL] [Abstract][Full Text] [Related]
8. Patient preference for triptan formulations: a prospective study with zolmitriptan.
Dowson A; Bundy M; Salt R; Kilminster S
Headache; 2007 Sep; 47(8):1144-51. PubMed ID: 17883519
[TBL] [Abstract][Full Text] [Related]
9. [Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
Perearnau P; Vuillemet F; Schick J; Weill G
Rev Neurol (Paris); 2006 Mar; 162(3):347-57. PubMed ID: 16585890
[TBL] [Abstract][Full Text] [Related]
10. Triptan use in Italy: Insights from administrative databases.
Da Cas R; Nigro A; Terrazzino S; Sances G; Viana M; Tassorelli C; Nappi G; Cargnin S; Pisterna A; Traversa G; Genazzani AA
Cephalalgia; 2015 Jun; 35(7):619-26. PubMed ID: 25246521
[TBL] [Abstract][Full Text] [Related]
11. Risk of ischemic complications related to the intensity of triptan and ergotamine use.
Wammes-van der Heijden EA; Rahimtoola H; Leufkens HG; Tijssen CC; Egberts AC
Neurology; 2006 Oct; 67(7):1128-34. PubMed ID: 17030745
[TBL] [Abstract][Full Text] [Related]
12. Triptans--why once?
Ifergane G; Wirguin I; Shvartzman P
Headache; 2006 Sep; 46(8):1261-3. PubMed ID: 16942470
[TBL] [Abstract][Full Text] [Related]
13. Predictors of adherence to triptans: factors of sustained vs lapsed users.
Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
[TBL] [Abstract][Full Text] [Related]
14. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
15. Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.
Frisk P; Sporrong SK; Ljunggren G; Wettermark B; von Euler M
Eur J Clin Pharmacol; 2016 Jun; 72(6):747-54. PubMed ID: 26922586
[TBL] [Abstract][Full Text] [Related]
16. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
17. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy.
Gori S; Morelli N; Acuto G; Caiola F; Iudice A; Murri L
Minerva Med; 2006 Dec; 97(6):467-77. PubMed ID: 17213783
[TBL] [Abstract][Full Text] [Related]
18. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
[TBL] [Abstract][Full Text] [Related]
19. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
[TBL] [Abstract][Full Text] [Related]
20. Effects of a polypharmacy edit and reduced quantity limits on the utilization of triptans and overall costs in an integrated health system.
Dunn JD; Cannon HE
Manag Care Interface; 2006 May; 19(5):46-51. PubMed ID: 16786970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
